• Home
  •      Global     
  • Contact
  • Sitemap
Value through Innovation24 May 2013
  • NEWS
  • VISION AND MISSION
  • CONGRESS CALENDAR
  • VIRTUAL SYMPOSIA
  • PATIENT CASES
  • MEDICAL EDUCATION
  • CLINICAL TRIALS
  • RESOURCE CENTRE
No flash player detected. For optimized usage of this website your browser should support shockwave flash.

Page content

jump to main navigation jump to meta navigation

TOP NEWS

 

Download your Spotlight-Version

  

SCIENTIFIC NEWS

16.05.2013

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

16.05.2013

ASCO 2013:  Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

For non U.S. Media Onlly
28.02.2013

Rare disease day: Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib* in patients with acute myeloid leukaemia

 -

For NON-US media only

Virtual Symposium of the Boehringer Ingelheim industry satellite symposium

37th ESMO Congress x
Friday 28 September - Tuesday 2 October, Vienna, Austria

Industry satellite symposium: Coming together as one: Working towards a better outcome in oncology

Watch Virtual Symposium

 

 

 

 

 

 

 

 

 

 

youtube-logo
nav_footer
back to top

Opinion Poll

Click to participate in the monthly inoncology poll and see how your answer compares with other health care professionals:

  • Accessibility Statement
  • Privacy Policy
  • Terms of use
  • Imprint
  • Print
  • Recommend
Boehringer Ingelheim
© 1999-2013 Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. All rights reserved
  • Accessibility statement
  • Homepage
  • Sitemap
  • Search
  • Contact
  • Print